Comparative safety of testosterone dosage forms

JAMA Internal Medicine

Volumn 175, Issue 7, 2015, Pages 1187-1196

  Layton, J Bradley ^a   Meier, Christoph R ^b   Sharpless, Julie L ^c   Stürmer, Til ^a   Jick, Susan S ^d   Brookhart, M Alan ^a  

^a IL   (United States)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE PROPIONATE; ANDROGEN; GEL;

ANDROGEN THERAPY; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DEATH; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; GEL; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPOGONADISM; INJECTION; MEDICARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; TRANSDERMAL PATCH; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM; ADULT; AGED; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; CUTANEOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANDROGENS; CARDIOVASCULAR DISEASES; GELS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TESTOSTERONE; TRANSDERMAL PATCH;

EID: 84937459792     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.1573     Document Type: Article

References (29)

1. Layton JB, Li D, Meier CR, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab. 2014;99(3):835-842.
2. Gan EH, Pattman S, Pearce SHS, Quinton R. A UK epidemic of testosterone prescribing, 2001-2010. Clin Endocrinol (Oxf). 2013;79(4):564-570.
3. Handelsman DJ. Pharmacoepidemiology of testosterone prescribing in Australia, 1992-2010. Med J Aust. 2012;196(10):642-645.
4. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173(15):1465-1466.
5. Walsh TJ, Shores MM, Fox AE, et al. Recent trends in testosterone testing, low testosterone levels, and testosterone treatment among Veterans [published online February 13, 2015]. Andrology. doi:10.1111/andr.12014.
6. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122.
7. FinkleWD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatalmyocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805. doi:10.1371/journal.pone.008580.
8. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836.
9. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050-2058.
10. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725-733.
11. Baillargeon J, Urban RJ, Kuo Y-F, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48 (9):1138-1144.
12. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3469-3478.
13. Swerdloff RS,Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-4510.
14. RayWA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.
15. Lakshminarayan K, Larson JC, Virnig B, et al. Comparison of Medicare claims versus physician adjudication for identifying stroke outcomes in the Women's Health Initiative. Stroke. 2014;45(3): 815-821.
16. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acutemyocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148(1):99-104.
17. Willey VJ, Bullano MF, Hauch O, et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther. 2004;26(7): 1149-1159.
18. Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):154-162.
19. Hammad TA,McAdams MA, Feight A, Iyasu S, Dal Pan GJ. Determining the predictive value of Read/OXMIS codes to identify incident acute myocardial infarction in the General Practice Research Database. Pharmacoepidemiol Drug Saf. 2008;17(12):1197-1201.
20. Jick H, Jick SS,Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302(6779):766-768.
21. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. In: Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. Cary, NC: SAS Institute Inc; 2001:214-226.
22. BrookhartMA,Wyss R, Layton JB, Stürmer T. Propensity scoremethods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes. 2013;6(5):604-611.
23. Fleiss JL. The statistical basis ofmeta-analysis. Stat Methods Med Res. 1993;2(2):121-145.
24. Glueck CJ, Richardson-Royer C, Schultz R, et al. Testosterone therapy, thrombophiliahypofibrinolysis, and hospitalization for deep venous thrombosis-pulmonary embolus: an exploratory, hypothesis-generating study. Clin Appl Thromb Hemost. 2014;20(3):244-249.
25. EisenbergML, Li S, Herder D, Lamb DJ, Lipshultz LI. Testosterone therapy and mortality risk. Int J Impot Res. 2015;27(2):46-48.
26. Jick SS, Hagberg KW. The risk of adverse outcomes in association with use of testosterone products: a cohort study using the UK-based general practice research database. Br J Clin Pharmacol. 2013;75(1):260-270.
27. Basaria S, Davda MN, Travison TG, Ulloor J, Singh R, Bhasin S. Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci. 2013;68(2): 153-160.
28. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95(6):2536-2559.
29. Greenland S, Lash TL. Bias analysis. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3rd ed. Baltimore, MD: Lippincott Williams &Wilkins; 2008:345-380.